scholarly journals Towards Growing a COIN in a Medical Research Community

2011 ◽  
Vol 26 ◽  
pp. 3-16 ◽  
Author(s):  
Peter A. Gloor ◽  
Francesca Grippa ◽  
Amy Borgert ◽  
Richard B. Colletti ◽  
George Dellal ◽  
...  
2007 ◽  
Vol 49 (11) ◽  
pp. 1184-1188 ◽  
Author(s):  
Gabriela Salmon Mulanovich ◽  
Andres G. Lescano ◽  
Víctor E. Gonzaga ◽  
David L. Blazes

Author(s):  
Siegfried Benkner ◽  
Chris Borckholder ◽  
Yuriy Kaniovskyi Alfredo Saglimbeni ◽  
Tomas Pariente Lobo ◽  
Piotr Nowakowski ◽  
...  

Author(s):  
Neeraja Sankaran ◽  
Ton van Helvoort

This paper uses a short ‘Christmas fairy-story for oncologists’ sent by Christopher Andrewes with a 1935 letter to Peyton Rous as the centrepiece of a reflection on the state of knowledge and speculation about the viral aetiology of cancer in the 1930s. Although explicitly not intended for public circulation at the time, the fairy-story merits publication for its significance in the history of ideas about viruses, which are taken for granted today. Andrewes and Rous were prominent members of the international medical research community and yet faced strong resistance to their theory that viruses could cause such tumours as chicken sarcomas and rabbit papillomas. By looking at exchanges between these men among themselves and other proponents of their theories and with their oncologist detractors, we highlight an episode in the behind-the-scenes workings of medical science and show how informal correspondence helped keep alive a vital but then heterodox idea about the role of viruses in causing cancer.


2016 ◽  
Vol 13 (6) ◽  
pp. 4-10
Author(s):  
O Yu Rebrova

Currently, there is no consistent view for the differentiation of basic and applied medical research in the Russian medical research community. Priority areas of applied science (but not fundamental) can be determined by the state on the basis of scientific methods and mechanisms implemented through competitive funding. The state as a qualified customer of applied research can be an important component of the development of Russian medical science.


Computation ◽  
2020 ◽  
Vol 8 (2) ◽  
pp. 53 ◽  
Author(s):  
Zhen Qiao ◽  
Hongtao Zhang ◽  
Hai-Feng Ji ◽  
Qian Chen

Since the outbreak of the 2019 novel coronavirus disease (COVID-19), the medical research community is vigorously seeking a treatment to control the infection and save the lives of severely infected patients. The main potential candidates for the control of viruses are virally targeted agents. In this short letter, we report our calculations on the inhibitors for the SARS-CoV-2 3CL protease and the spike protein for the potential treatment of COVID-19. The results show that the most potent inhibitors of the SARS-CoV-2 3CL protease include saquinavir, tadalafil, rivaroxaban, sildenafil, dasatinib, etc. Ergotamine, amphotericin b, and vancomycin are most promising to block the interaction of the SARS-CoV-2 S-protein with human ACE-2.


2021 ◽  
Vol 11 (6) ◽  
Author(s):  
Patrick F. Chinnery ◽  
Jonathan J. Pearce ◽  
Anna M. Kinsey ◽  
Joanna M. Jenkinson ◽  
Glenn Wells ◽  
...  

Here, we consider how the lessons we learned in 2020 from funding COVID-19 research could have a long-term impact on the way that we fund medical research. We look back at how UK government funding for COVID-19 medical research evolved, beginning with the early calls for proposals in February that pump-primed funding for vaccines and therapeutics, and culminating in the launch of the government's National Core Studies programme in October. We discuss how the research community mobilized to submit and review grants more rapidly than ever before, against a background of laboratory and office closures. We also highlight the challenges of running clinical trials as the number of hospitalized patients fluctuated with different waves of the disease.


Author(s):  
Nicholas Kelling ◽  
Christopher Ward ◽  
David Malin ◽  
William Buras ◽  
Scott Hetherington

The lack of research replicability is becoming more of a concern in many fields. The medical research community and specifically the National Institutes of Health are concerned about how this issue will affect the well-being of the field (Collins & Tabak, 2014). However, this situation represents an opportunity to showcase how human factors can act as a solution through a combination of usability and human systems integration. The current work details how the development of a software platform designed to address replicability and reproducibility concerns in drug dependency research was informed by human factors principles from early development.


Nature ◽  
2000 ◽  
Vol 405 (6788) ◽  
pp. 722-722
Author(s):  
David Spurgeon

2005 ◽  
Vol 12 (4) ◽  
pp. 357-372 ◽  
Author(s):  
Asim Sheikh

AbstractDirective 95/46/EC on the Protection of Individuals with regard to the Processing of Personal Data and on the Free Movement of Such Data has been transposed into national law and is now the Data Protection (Amendment) Act, 2003.The Directive and the transposing Act provide for new obligations to those processing data. The new obligation of primary concern is the necessity to obtain consent prior to the processing of data (Article 7, Directive 95/46/EC). This has caused much concern especially in relation to 'secondary data' or 'archived data'.There exist, what seem to be in the minds of the medical research community, two competing interests: (i) that of the need to obtain consent prior to processing data and (ii) the need to protect and foster medical research. At the same time as the introduction of the Act, other prior legislation, i.e. the Freedom of Information Act, 1997-2003, has encouraged candour within the doctor-patient relationship and the High Court in Ireland, in the case of Geoghegan v. Harris, has promulgated the 'reasonable-patient test' as being the correct law in relation to the disclosure of risks to patients. The court stated that doctors have a duty to disclose all material risks to patients. The case demonstrates an example of a move toward a more open medical relationship. An example of this rationale was also recently seen in the United Kingdom in the House of Lords decision in Chester v. Afshar. Within the medical research community in Ireland, the need to respect the autonomy of patients and research participants by providing information to such parties has also been observed (Sheikh A. A., 2000 and Irish Council for Bioethics, 2005).Disquiet has been expressed in Ireland and other jurisdictions by the medical research communities in relation to the exact working and meaning of the Directive and therefore the transposing Acts (Strobl et al). This may be due to the fact that, as observed by Beyleveld "The Directive makes no specific mention of medical research and, consequently, it contains no provisions for medical research as an explicitly delineated category." (Beyleveld D., 2004) This paper examines the Irish Act and discusses whether the concerns expressed are well-founded and if the Act is open to interpretation such that it would not hamper medical research and public health work.


Sign in / Sign up

Export Citation Format

Share Document